Effect of combined therapy using balloon-occluded arterial infusion of cisplatin and hemodialysis with concurrent radiation for locally invasive bladder cancer

Haruhito Azuma, Yatsugu Kotake, Kazuhiro Yamamoto, Takeshi Sakamoto, Satoshi Kiyama, Takanobu Ubai, Teruo Inamoto, Kiyoshi Takahara, Mitsuru Matsuki, Naoki Segawa, Nobuhisa Shibahara, Yoji Katsuoka

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: We tested the usefulness of combined therapy usin balloon-occluded arterial infusion (BOAI) of cisplatin and hemodialysis, which delivers an extremely high concentration of cisplatin to the site of a tumor without systemic adverse effects, with concurrent radiation in patients with locally advanced bladder cancer. Methods: Patients underwent transurethral resection of the bladder tumor followed by BOAI of cisplatin (100, 200, or 300 mg) concurrent with hemodialysis, via both common iliac veins, for 2 hours after initiation of BOAI. A total of 60.4 Gy of radiation was delivered, starting from the day of BOAI. Results: Forty-one patients (30 males and 11 females, aged 55-98 years) were enrolled and assessable for toxicity and response. None of the patients suffered grade II or more severe toxicities; some experienced grade I blood/bone marrow toxicity, gastrointestinal toxicity, or neuropathy. All patients with histologically confirmed transitional cell carcinoma stage T2 or T3 (29 patients) achieved a complete response and were able to retain their bladder with no evidence of recurrent disease or distant metastasis at a mean followup of 132 weeks (range 8-648 weeks) after therapy. Patients with stage T4 tumors, besides transitional cell carcinoma, or lymph node involvement had stable or progressive disease. Conclusion: This therapy is a new strategy for patients with locally advanced bladder cancer. It can be a curative treatment not only in patients for whom total cystectomy is indicated, but also in patients whose condition is not amenable to curative treatment and for whom merely palliative treatment would otherwise seem the only option.

Original languageEnglish
Pages (from-to)11-21
Number of pages11
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume31
Issue number1
DOIs
Publication statusPublished - 01-02-2008

Fingerprint

Urinary Bladder Neoplasms
Cisplatin
Renal Dialysis
Radiation
Therapeutics
Transitional Cell Carcinoma
Iliac Vein
Radiation Dosage
Cystectomy
Palliative Care
Neoplasms
Urinary Bladder
Lymph Nodes
Bone Marrow
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Azuma, Haruhito ; Kotake, Yatsugu ; Yamamoto, Kazuhiro ; Sakamoto, Takeshi ; Kiyama, Satoshi ; Ubai, Takanobu ; Inamoto, Teruo ; Takahara, Kiyoshi ; Matsuki, Mitsuru ; Segawa, Naoki ; Shibahara, Nobuhisa ; Katsuoka, Yoji. / Effect of combined therapy using balloon-occluded arterial infusion of cisplatin and hemodialysis with concurrent radiation for locally invasive bladder cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2008 ; Vol. 31, No. 1. pp. 11-21.
@article{69d03704115e439e8f8160e0aaa2904c,
title = "Effect of combined therapy using balloon-occluded arterial infusion of cisplatin and hemodialysis with concurrent radiation for locally invasive bladder cancer",
abstract = "Objective: We tested the usefulness of combined therapy usin balloon-occluded arterial infusion (BOAI) of cisplatin and hemodialysis, which delivers an extremely high concentration of cisplatin to the site of a tumor without systemic adverse effects, with concurrent radiation in patients with locally advanced bladder cancer. Methods: Patients underwent transurethral resection of the bladder tumor followed by BOAI of cisplatin (100, 200, or 300 mg) concurrent with hemodialysis, via both common iliac veins, for 2 hours after initiation of BOAI. A total of 60.4 Gy of radiation was delivered, starting from the day of BOAI. Results: Forty-one patients (30 males and 11 females, aged 55-98 years) were enrolled and assessable for toxicity and response. None of the patients suffered grade II or more severe toxicities; some experienced grade I blood/bone marrow toxicity, gastrointestinal toxicity, or neuropathy. All patients with histologically confirmed transitional cell carcinoma stage T2 or T3 (29 patients) achieved a complete response and were able to retain their bladder with no evidence of recurrent disease or distant metastasis at a mean followup of 132 weeks (range 8-648 weeks) after therapy. Patients with stage T4 tumors, besides transitional cell carcinoma, or lymph node involvement had stable or progressive disease. Conclusion: This therapy is a new strategy for patients with locally advanced bladder cancer. It can be a curative treatment not only in patients for whom total cystectomy is indicated, but also in patients whose condition is not amenable to curative treatment and for whom merely palliative treatment would otherwise seem the only option.",
author = "Haruhito Azuma and Yatsugu Kotake and Kazuhiro Yamamoto and Takeshi Sakamoto and Satoshi Kiyama and Takanobu Ubai and Teruo Inamoto and Kiyoshi Takahara and Mitsuru Matsuki and Naoki Segawa and Nobuhisa Shibahara and Yoji Katsuoka",
year = "2008",
month = "2",
day = "1",
doi = "10.1097/COC.0b013e318136e27a",
language = "English",
volume = "31",
pages = "11--21",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Effect of combined therapy using balloon-occluded arterial infusion of cisplatin and hemodialysis with concurrent radiation for locally invasive bladder cancer. / Azuma, Haruhito; Kotake, Yatsugu; Yamamoto, Kazuhiro; Sakamoto, Takeshi; Kiyama, Satoshi; Ubai, Takanobu; Inamoto, Teruo; Takahara, Kiyoshi; Matsuki, Mitsuru; Segawa, Naoki; Shibahara, Nobuhisa; Katsuoka, Yoji.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 31, No. 1, 01.02.2008, p. 11-21.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of combined therapy using balloon-occluded arterial infusion of cisplatin and hemodialysis with concurrent radiation for locally invasive bladder cancer

AU - Azuma, Haruhito

AU - Kotake, Yatsugu

AU - Yamamoto, Kazuhiro

AU - Sakamoto, Takeshi

AU - Kiyama, Satoshi

AU - Ubai, Takanobu

AU - Inamoto, Teruo

AU - Takahara, Kiyoshi

AU - Matsuki, Mitsuru

AU - Segawa, Naoki

AU - Shibahara, Nobuhisa

AU - Katsuoka, Yoji

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Objective: We tested the usefulness of combined therapy usin balloon-occluded arterial infusion (BOAI) of cisplatin and hemodialysis, which delivers an extremely high concentration of cisplatin to the site of a tumor without systemic adverse effects, with concurrent radiation in patients with locally advanced bladder cancer. Methods: Patients underwent transurethral resection of the bladder tumor followed by BOAI of cisplatin (100, 200, or 300 mg) concurrent with hemodialysis, via both common iliac veins, for 2 hours after initiation of BOAI. A total of 60.4 Gy of radiation was delivered, starting from the day of BOAI. Results: Forty-one patients (30 males and 11 females, aged 55-98 years) were enrolled and assessable for toxicity and response. None of the patients suffered grade II or more severe toxicities; some experienced grade I blood/bone marrow toxicity, gastrointestinal toxicity, or neuropathy. All patients with histologically confirmed transitional cell carcinoma stage T2 or T3 (29 patients) achieved a complete response and were able to retain their bladder with no evidence of recurrent disease or distant metastasis at a mean followup of 132 weeks (range 8-648 weeks) after therapy. Patients with stage T4 tumors, besides transitional cell carcinoma, or lymph node involvement had stable or progressive disease. Conclusion: This therapy is a new strategy for patients with locally advanced bladder cancer. It can be a curative treatment not only in patients for whom total cystectomy is indicated, but also in patients whose condition is not amenable to curative treatment and for whom merely palliative treatment would otherwise seem the only option.

AB - Objective: We tested the usefulness of combined therapy usin balloon-occluded arterial infusion (BOAI) of cisplatin and hemodialysis, which delivers an extremely high concentration of cisplatin to the site of a tumor without systemic adverse effects, with concurrent radiation in patients with locally advanced bladder cancer. Methods: Patients underwent transurethral resection of the bladder tumor followed by BOAI of cisplatin (100, 200, or 300 mg) concurrent with hemodialysis, via both common iliac veins, for 2 hours after initiation of BOAI. A total of 60.4 Gy of radiation was delivered, starting from the day of BOAI. Results: Forty-one patients (30 males and 11 females, aged 55-98 years) were enrolled and assessable for toxicity and response. None of the patients suffered grade II or more severe toxicities; some experienced grade I blood/bone marrow toxicity, gastrointestinal toxicity, or neuropathy. All patients with histologically confirmed transitional cell carcinoma stage T2 or T3 (29 patients) achieved a complete response and were able to retain their bladder with no evidence of recurrent disease or distant metastasis at a mean followup of 132 weeks (range 8-648 weeks) after therapy. Patients with stage T4 tumors, besides transitional cell carcinoma, or lymph node involvement had stable or progressive disease. Conclusion: This therapy is a new strategy for patients with locally advanced bladder cancer. It can be a curative treatment not only in patients for whom total cystectomy is indicated, but also in patients whose condition is not amenable to curative treatment and for whom merely palliative treatment would otherwise seem the only option.

UR - http://www.scopus.com/inward/record.url?scp=42449153865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42449153865&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e318136e27a

DO - 10.1097/COC.0b013e318136e27a

M3 - Article

C2 - 18376222

AN - SCOPUS:42449153865

VL - 31

SP - 11

EP - 21

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -